Bristol-Myers Seeks To Bust Genentech Cancer Drug Patents
Bristol-Myers Squibb Co. on Friday filed suit in California federal court that two Genentech Inc. patents relating to blood cancer treatment are invalid and that Bristol-Myers Squibb's antibody-producing cancer drugs Erbitux...To view the full article, register now.
Already a subscriber? Click here to view full article